Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial.
Qin S, Li J, Zhong H, Jin C, Chen L, Yuan X, Fan Q, Chen K, Cao P, Xiao J, Jiang D, Zhang T, Zhang H, Wang X, Wang W, Han L, Wang Q, Zhu J; Serplulimab-MSI-H Investigators.
Qin S, et al. Among authors: han l.
Br J Cancer. 2022 Dec;127(12):2249. doi: 10.1038/s41416-022-02043-7.
Br J Cancer. 2022.
PMID: 36323881
Free PMC article.
No abstract available.